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Abstract
Our understanding of congenital heart defects has been recently advanced by whole exome
sequencing projects, which have identified de novo mutations in many genes encoding epigenetic
regulators. Notably, multiple subunits of SWI/SNF chromatin-remodeling complexes have been
identified as strong candidates underlying these defects because they physically and functionally
interact with cardiogenic transcription factors critical to cardiac development, such as TBX5,
GATA-4, and NKX2-5. While these studies indicate a critical role of SWI/SNF complexes in
cardiac development and congenital heart disease, many exciting new discoveries have identified
their critical role in the adult heart in both physiological and pathological conditions involving
multiple cell types in the heart, including cardiomyocytes, vascular endothelial cells, pericytes,
and neural crest cells. This review summarizes the role of SWI/SNF chromatinremodeling
complexes in cardiac development, congenital heart disease, cardiac hypertrophy, and vascular
endothelial cell survival. Although the clinical relevance of SWI/SNF mutations has traditionally
been focused primarily on their role in tumor suppression, these recent studies illustrate their
critical role in the heart whereby they regulate cell proliferation, differentiation, and apoptosis of
cardiac derived cell lines.
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Introduction
Our traditional focus on the regulation of cardiac disease and congenital causes of
cardiovascular disease involves a focus on the cell signaling pathways and downstream
transcription factors involved. However, the emerging field of epigenetics is offering a new
way to look how development, congenital cardiac disease, and the diseased heart is
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regulated through chromatin remodeling under different physiological and pathological
conditions. Chromatin modeling and histone modifications play an essential role in cardiac
development and disease, including pathologic cardiac hypertrophy. These chromatin
remodeling complexes, including the SWI/SNF (switching defective/sucrose non-
fermenting) complex, are comprised of 9-12 subunits, including ATPase subunits encoded
by either brm (brahma) or brg1 (brahma-related gene 1) [1]. In this review, we discuss our
current understanding of SWI/SNF complexes, their regulation of in congenital cardiac
defects, cardiac development, and cardiac disease states. We then discuss new studies
implicating, for the first time, their role in the maintenance of the healthy adult heart. The
use of the new classes of drugs that regulate SWI/SNF associated histone acetylation,
including histone deacetylase (HDAC) inhibitors, will be considered for their possible
unintended affects in the cardiovascular system.
De Novo Mutations in Epigenetic Regulators Cause Congenital Heart
Defects
Developmental cardiac defects represent the most common serious birth defects, affecting
~2% of newborns with abnormalities that can range from mild, where the effects might not
be observed until adulthood, to severe, with immediate morbidity or mortality [2].
Congenital heart defects affect 1.35 million patients each year, and they are also identified in
10% of stillbirths [3], where they are presumed to be a common cause of fetal demise. The
importance of genetics in congenital heart disease is supported by a growing list of genes
that are mutated [4]. Genes encoding cardiogenic transcripton factors, such as tbx1, tbx5,
tbx20, gata4, and gata6have received particular attention for good reason considering their
important role in the transcriptional regulation of downstream target genes [4]. However,
transcription factors generally function in combination with histone-modifying enzymes and
chromatin-remodeling complexes to epigenetically regulate gene expression. For this reason,
it stands to reason that many yet to be identified mutations occur in epigenetic regulators [5].
Indeed, the advent of high-throughput sequencing platforms has led to whole-exome
sequencing projects that have recently identified mutations in many genes encoding histone-
modifying enzymes and components of chromatin-remodeling complexes [6–13]. An
important feature of these sequencing projects is that parent-offspring trios were sequenced
in which the proband was a child with severe congenital cardiac defects who had no first-
degree relatives with structural heart disease. Importantly, the mutations in these epigenetic
regulatory genes occurred de novowhich implies that they have dosage-sensitive cardiac
functions and explains why these genes were not identified in previous pedigree analyses.
Unlike cardiogenic transcription factors, these epigenetic regulators are broadly expressed,
interact with many diverse transcription factors to regulate hundreds to thousands of genes,
and have pleiotropic functions both within and outside of the heart. As a result, a sub-set of
heterozygous loss-of-function mutations result in severe cardiac defects that preclude the
viability and fertility necessary for a pedigree to be established. Consequently, one might
expect exome sequencing projects to continue identifying novel genes that cause congenital
heart defects.
Mutations in SWI/SNF Subunits Result in Congential Syndromes that
Include Cardiac Defects
Several independent exome sequencing projects have recently identified de novo mutations
in 4 different SWI/SNF subunits in three congenital syndromes that include cardiac defects:
Coffin-Siris syndrome (CSS), Nicolaides-Baraitser syndrome (NCBRS), and ARID1B-
related intellectual disability (ID) syndrome [9–13]. Patients with CSS, NCBRS, and ID
Bevilacqua et al. Page 2













syndromes display a wide variety of symptoms including severe intellectual deficits and
cardiac defects such as atrial/ventricular septal defects, patent ductus arteriosus (PDA),
mitral and pulmonary atresia, mitral and tricuspid regurgitation, aortic stenosis, coarctation
of the aorta, and single right ventricle [14].
SWI/SNF chromatin-remodeling complexes consist of 9–12 subunits and are recruited by
sequence-specific transcription factors to the promoters of numerous target genes, where
they slide or evict nucleosomes near the transcripton start site (TSS) to regulate RNA
Polymerase II occupancy and transcriptional initiation (Figures 1 and 2). Depending on
whether a transcriptional activator or repressor recruits SWI/SNF, transcription can be
upregulated or downregulated. Each SWI/SNF complex utilizes either BRG1 (also known as
SMARCA4) or BRM (also known as SMARCA2) as alternative catalytic subunits with
DNA-dependent ATPase activity [15]. The energy of ATP hydrolysis is harnessed to disrupt
histone-DNA contacts and move nucleosomes away from the TSS or toward the TSS. BRG1
and BRM represent 2 of the 4 SWI/SNF subunits that are known to be mutated in CSS and
NCBRS. The non-catalytic subunits of SWI/SNF are often referred to as BAFs (BRG1 or
BRM associated factors with a number referring to the molecular mass of the protein). Each
SWI/SNF complex contains a single ARID (AT-rich interacting domain)-containing subunit.
SWI/SNF complexes are subdivided into BAF and PBAF complexes based on their catalytic
and ARID subunits (Figure 1). BAF complexes are catalyzed by either BRG1 or BRM and
incorporate either BAF250a or BAF250b (also known as ARID1a and ARID1b,
respectively), whereas PBAF complexes are exclusively catalyzed by BRG1 and incorporate
BAF200 (also known as ARID2). The ARID subunits are arguably the next best understood
subunits within SWI/SNF complexes. Each ARID subunit can bind to DNA in a non-
specific manner and is believed to influence SWI/SNF recruitment by physically associating
with different transcription factors [16, 17]. BAF250a and BAF250b are the other 2 subunits
mutated in CSS and NCBRS, and BAF250b is also mutated in ID syndrome. The clinical
importance of the catalytic and ARID-containing subunits is underscored by the observation
that BRG1, BRM, BAF250a, and BAF250b are important tumor-suppressor genes that are
recurrently mutated or silenced in a variety of human primary tumors [11, 18].
Congenital cardiac defects can arise from abnormal development of cardiomyocytes as well
as vascular endothelial cells, pericytes (i.e., a distinct population of vascular smooth muscle
cells), and neural crest-derived structures such as semilunar valves and the septum. It is
noteworthy that SWI/SNF complexes play an important role in each of these lineages based
on gene-targeting experiments in mice. For example, constitutive null mutations of Baf180
and Baf60c result in mid-gestation lethality due to cardiac defects. Constitutive null
mutations of Brg1, Baf250a/Arid1a, Baf155and Baf47/Snf5 result in even earlier lethality at
the peri-implantation stage. Although this early embryonic lethality occurs before the onset
of cardiac development, Cre/loxP conditional mutations have established a role in
cardiovascular development. The sections that follow will summarize this work for each cell
lineage and emphasize mechanistic insights that are clinically relevant.
BRG1 and cardiomyocyte development
Brg1 genetically interacts with tbx5 [19], and the BAF60c subunit facilitates a physical
interaction between brg1 and the cardiogenic transcription factors TBX4, GATA4, and
NKX2-5 [20]. Furthermore, increased expression of BAF60c plus TBX5 and GATA4 can
program non-cardiac mesoderm to become beating cardiomyocytes [21]. Based on these
findings, it is not surprising that BRG1 and SWI/SNF complexes play an important role in
cardiomyocyte development. Experimentally, a conditional mutation of Brg1 in myocardial
progenitors within the secondary heart field resulted in hypoplastic right ventricles and
outflow tracts, which culminated in embryonic lethality at E10.5. A second Brg1 conditional
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mutation in the myocardium resulted in a thin myocardium, lack of a septum, and embryonic
lethality at E11.5 [22]. This phenotype may be explained, in part, by BRG1 activating
Bmp10 mRNA levels to promote myocardial proliferation. A third conditional mutation of
Brg1which was restricted to the developing endocardium, also resulted in embryonic
lethality at E10.5-11.5 [23]. These endocardium mutants exhibited hypotrabeculation and a
lack of cardiac jelly. This work revealed a role for BRG1 in the transcriptional repression of
Adamts1which encodes an extracellular protease, to promote myocardial trabeculation and
prevent the premature degradation of cardiac jelly.
BAF- and PBAF-specific subunits in cardiomyocyte development
Because BRG1 catalyzes both BAF and PBAF complexes, the aforementioned Brg1
conditional mutations cannot provide insight into the relative importance of these two
categories of SWI/SNF complexes. To evaluate BAF versus PBAF functions, it is necessary
to analyze mutations in subunits that are specifically incorporated into BAF or PBAF
complexes but not both. As mentioned above, BAF250a is exclusively incorporated into
BAF complexes. A conditional mutation of Baf250a in myocardial progenitors within the
secondary heart field caused a phenotype similar to Brg1 mutants with delayed development
of the right ventricle, decreased trabeculation, defective formation of the ventricular septum
and outflow tract, and embryonic lethality around E13 [24].
By mutating Baf250a in ES cells, it was shown that BAF250a is crucial for the
differentiation of cardiac progenitor cells into mature cardiomyocytes [24]. Gene expression
was altered with decreased Bmp10, ErbB2and ErbB4 mRNA levels, which, in combination,
may have contributed to the decreased trabeculation and myocardial development [24–28].
Nkx2.5 and Mef2c mRNA levels were also decreased, and this suggests that SWI/SNF might
be part of an autoregulatory loop to maintain the expression of cardiogenic transcription
factors. ChIP assays demonstrated that BRG1 occupancy at the Nkx2.5, Mef2c and Bmp10
promoters was diminished in Baf250a mutant cells, which suggests that BRG1 is recruited
to these sites in a BAF250a-dependent manner. Consistent with the idea that SWI/SNF
complexes alter chromatin structure, DNase I hypersensitivity assays showed that decreased
expression of target genes in Baf250a mutant cells correlated with a more “closed”
chromatin configuration (i.e., indicative of higher nucleosome density) of the corresponding
promoter regions. [24].
A point mutation in the ARID domain of BAF250a has also been reported that behaves as a
hypomorph with similar cardiac defects including a lack of ventricular trabeculation and
ventricular septal defects with mid-gestation lethality at E10.5-12.5 [16]. This work also
suggests that BAF250a is important for SWI/SNF recruitment to target genes including
thrombospondin 1 (Thbs1). This is an interesting target gene because the thrombospondin
family has been implicated as cardioprotective factors in numerous incidences of
cardiovascular pathology [29, 30].
In contrast to BAF250a, BAF180 as well as BAF200 are unique to PBAF complexes.
BAF180 does not have an ARID domain but instead has 6 bromodomains that bind to
acetylated histones. This is believed to influence the recruitment of PBAF complexes (which
stands for polybromo BAF complexes because of BAF180) such that it has different targets
than BAF complexes. As a result, PBAF complexes can potentiate the transcriptional
activation mediated by certain nuclear receptors such as RXRα, VDR and PPARγ.
Constitutive null mutants of Baf180 have a variety of cardiac defects including hypoplastic
ventricles and ventricular-septal defects with embryonic lethality occurring at E12.5-E15.5
[31, 32]. Consistent with PBAF cooperating with RXRα, a number of retinoic acid target
genes such as RXRβ2 and CRABPII were altered in Baf180 mutants. Therefore, both BAF
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and PBAF complexes are required for cardiomyocyte development although additional work
will be necessary to understand how they are different functionally.
BAF60c and cardiomyocyte development
Although BAF60c is one of three alternative BAF60 subunits, it is expressed in a tissue-
specific manner with high levels in the developing heart [20]. As a result, it is the
predominant BAF60 subunit in both BAF and PBAF complexes. An RNAi-mediated
approach was used to perturb BAF60c in all embryonic tissues, and this resulted in a variety
of cardiac defects including abnormal looping, hypoplastic ventricles, hypotrabeculation,
and a shortened outflow tract with lethality at E10-11 [20]. BAF60c activates Notch and
Nodal signaling pathways, which is believed to be important for the looping phenotype in
Baf60c knockdown embryos. BAF60c is also noteworthy because it interacts with Tbx5,
Nkx2.5, and GATA-4, and increased expression of BAF60c, TBX5, and GATA4 in non-
cardiac mesoderm can drive their differentiation into beating cardiomyocytes[21].
Considering that BRG1, BAF250a, BAF180, and BAF60c are subunits of SWI/SNF
complexes, it is reassuring that there is so much overlap among the mutant phenotypes. It is
also reassuring that the defects that have been observed, such as defective outflow tract
remodeling, is similar to what is observed in human congenital cardiac defects. Cre/loxP
conditional mutations have also been used to investigate the role of BRG1 in the
development of vascular endothelial cells, pericytes, and neural crest derived cardiac
structures that when perturbed contribute to human congenital cardiac defects. The role of
BRG1 in each of these cell types is discussed below.
Vascular endothelial cells
A Tie2-Cre conditional mutation of Brg1 resulted in embryonic lethality at E11.5. Although
a defect in erythropoiesis is believed to be the cause of death, there were widespread defects
in VEC development within the yolk sac [33]. The mutant vessels were thin, disconnected,
and did not sprout/regress properly. Vasculogenesis was relatively normal in the embryo
proper, including the developing heart, but the early embryonic lethality may have precluded
these defects from being observed at a slightly later stage. Characterization of the mutant
phenotype revealed dual roles for BRG1 in Wnt signaling [34, 35], which is consistent with
several other reports implicating SWI/SNF in Wnt signaling, and that BRG1 also promotes
COUP-TFII expression and venous specification during development [36]. Yolk sac
angiogenesis defects have also been observed in Baf155 constitutive mutants that develop
beyond the peri-implantation stage because of partial rescue from a Baf155 transgene [37].
In addition to having cardiomyocyte defects, Baf180 constitutive mutants have defective
coronary vessel development around the ventricle and within the myocardium [31, 32].
These vessels are derived from epicardial cells, and the coronary vessel defects are proposed
to be due to a problem with the epithelial-to-mesenchymal transition and the migration of
epicardial cells.
Pericytes
A conditional mutation of Brg1 in smooth muscle resulted in a subset of the mutants dying
during the early postnatal stage due to cardiopulmonary defects [38]. The mutants exhibited
patent ductus arteriosus (PDA), ventricular septal derfects, and had dilated cardiac chambers
consistent with left-right shunt and volume overload congestive heart failure. This
phenotype is consistent with in vitro experiments demonstrating that BRG1 and BRM are
required for maintaining the expression of several smooth muscle specific protein-coding
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genes and microRNAs [39, 40]. This transcriptional regulatory mechanism was mediated, in
part, by enabling myocardin to increase serum response factor (SRF) at the target genes.
A critical component of the vascular remodeling that occurs in the pathophysiology of
vascular diseases include the phenotypic transition of vascular smooth muscle cells
(VSMCs) to proliferate, migrate, and invade [41–43]. The gasotransmitter H2S exerts a wide
range of control on the proliferation and survival of VSMCs through the MAPK pathway
[44, 45]. Recent studies have identified that BRG1 is crucial for H2S-induced inhibition of
vascular smooth muscle cell proliferation using overexpression and knockdown of BRG1
[46]. Interestingly, H2S in return inhibits BRG1 transcription and expression by preventing
its recruitment to the promoters of BRG1-regulated genes, including Pcna, Ntf3, and Pdgfα
[46]. By altering the chromatic remodeling in vascular smooth muscle cells, H2S inhibits
BRG1 regulation, altering the phenotype that would be expected in disease.
Neural crest
Neural crest cells originate from the dorsal neural tube and migrate to many sites in the
developing embryo where they differentiate into diverse cell types including cardiovascular
structures. For example, neural crest cells contribute to the cardiac outflow tract, vascular
smooth muscle cells, and the muscular septum of the aorta and pulmonary trunk. A
conditional mutation of Brg1 in neural crest cells resulted in embryonic lethality at
E11.5-12.5, and these mutants had abnormal vascular development and shortened outflow
tracts [47]. This phenotype was associated with aberrant apoptosis and cell proliferation, and
BRG1 suppressed apoptosis signal regulating kinase 1 (Ask1) and the cycle-dependent
kinase inhibitor p21. BRG1 also promoted myosin heavy chain 11 (Myh11) to differentiate
neural crest cells into vascular smooth muscle cells. Finally, the Brg1 neural crest phenotype
resembled the congential heart defects observed in human CHARGE syndrome. CHARGE
syndrome is due to mutations in the CHD7 chromatin remodeler [7], and BRG1 and CHD7
both bind to the PlexinA2 promoter and co-regulate its expression, which encodes a
semaphoring to guide neural crest cells to the outflow tract [47].
BRG1 and pathological cardiac hypertrophy
BRG1 expression is increased in cardiomyocytes in response to cardiac stress [22], and this
finding parallels another study that reported increased expression of BRG1, BAF180, and
BAF60c during the cardiac hypertrophy [48]. However, all of the mouse models described
above conferred embryonic lethality, which precluded a functional assessment of SWI/SNF
in this process. Therefore, to circumvent embryonic lethality, Brg1 was inducibly mutated in
the myocardium of adult mice, and this revealed a crucial role in cardiac hypertrophy
relevant to human heart disease [22]. The temporally-induced Brg1 mutants were viable and
appeared normal under basal conditions. However, when transverse aortic constriction (TAC
banding) was use to pressure overload the heart and induce cardiac hypertrophy, the mutants
exhibited minor hypertrophy compared to controls.
The normal response to hypertrophy involves extensive transcriptional and metabolic
reprogramming to a fetal-like state. Transcriptionally, the cardiogenic transcription factors,
which are normally expressed only during development, are re-expressed during
hypertrophy, and there is also a switch in myosin heavy chain (MHC) isoforms from α-
MHC to β-MHC. Metabolically, cardiomyocytes modulate their primary use of fatty acids as
their preferred energy source and revert to using glucose to generate ATP. Considering that
there is not a cardiac stem population capable of significant regeneration, these
transcriptional and metabolic changes may represent an attempt by cardiomyocytes to switch
from a quiescent, adult-type state to a proliferative, fetal-like state for the purpose of
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regeneration. Not only was BRG1 shown to be required for hypertrophy, but BRG1 has been
found to occupy the MHC promoters to regulate their expression [22]. BRG1 formed a
complex with PARP1 and several histone deacetylases (HDACs) to induce the α- to β-MHC
switch in hearts from TAC-banded mice. These findings are clinically relevant to humans
because certain patients with hypertrophic cardiomyopathy had BRG1 levels that were
correlated with disease severity and changes in myosin heavy chain (MHC) isoforms [22].
Functional compensation of homologous SWI/SNF subunits in post-natal
homeostasis
While BAF and PBAF complexes are defined by their catalytic and ARID-domain
containing subunits (Figure 1), the BAF complexes can be further subdivided. These
complexes are catalyzed by either BRG1 or BRM and contain either BAF250a or BAF250b
(Figure 1). Although the BRG1-BRM and BAF250a-BAF250b homolog pairs are highly
conserved (75% and 50% amino-acid identity, respectively), they are functionally distinct.
BRG1 and BAF250a are essential for embryonic development [49, 50], whereas BRM and
BAF250b are dispensable since homozygotes are viable and fertile [32, 51].
The difference between BRG1 and BRM may be due to divergent N-termini, which
influences the transcription factors they can physically interact with and the target genes
they are recruited to [52]. Another possibility is that BRG1 is known to be expressed at
higher levels than BRM in the early embryo so BRG1 may compensate for the loss of BRM
but not vice versa [50, 53]. However, the gap between BRG1 and BRM expression levels
does not apply to many differentiated tissues, and BRM may therefore be important for post-
natal cardiovascular function and homeostasis. This is, in fact, the case for vascular
endothelial cells. Brg1 is required for the development of this lineage in embryos, whereas
Brm is not. Furthermore the Brg1 mutant phenotype is not exacerbated by BRM
deficiency[33, 35]. Yet an inducible mutation of Brg1 in vascular endothelial cells did not
confer an obvious phenotype in adult mice. This lack of a mutant phenotype was due to Brm
redundancy because when the same Brg1 mutation was induced on a Brm-deficient
background, the double mutants exhibited a vascular endothelial cell defect most evident in
the heart (Figure 2), resulting in death within 1 month [54]. Mechanistically, the absence of
BRG1 and BRM in VECS resulted vascular leakage, cardiac hemorrhage, and secondary
cardiomyocyte cell death due to ischemia and ventricular dissections were identified as the
underlying pathogenesis (Figure 2) [54].
Conclusions
As our understanding of new ways to regulate transcription factors and gene expression
expands, so does our understanding of cardiac development, congenital heart disease,
cardiac disease and the maintenance of the healthy heart. In this review, we summarized the
emerging field of epigenetic regulation of transcription factors by chromatin remodeling and
histone modification by the ATP-dependent SWI/SNF (switching defective/sucrose non-
fermenting) complex, comprised of ATPase subunits encoded by either BRG1 (brahma-
related gene 1) or BRM (brahma). While these subunits have been implicated in cardiac
development by regulating transcription factors, mutations in these subunits can result in
human congenital heart disease because of defects in many parallel transcription factors
including TBX5 and GATA4 (see Table 1). A growing appreciation of BRG1 and BRM in
the development of heart failure and the maintenance of pericytes and vascular endothelial
cells in the healthy heart illustrate the important of SWI/SNF in maintaining an intact
cardiovascular system for survival. While we are beginning to understand the specific
transcription factors and genes regulated by different combinations of SWI/SNF complexes
in vivoour understanding of the ATPase subunits BRG1 and BRM by miRNA and post-
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translational modification by ubiquitin and SUMO is in its infancy [55, 56]. Since human
SWI/SNF complexes interacts with HDAC proteins with histone deacetylase activities
(HDAC) [57], care should be taken with the increased used of HDAC inhibitors as cancer
therapies for their unintended effects on cardiac function maintenance, in light of recent
studies implicating the importance of BRG1 and BRM in the adult heart experimentally
[58].
Acknowledgments
The authors thank Sarah Edwards for her editorial assistance with this manuscript.
Non-Standard Abbreviations
BAF BRG1/BRM-associated factor
BRG1 brahmarelated gene 1
BRM brahma
SMC smooth muscle cell
SWI/SNF mating type, switching/sucrose non-fermenting
VEC vascular endothelial cell
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Figure 1. Mammalian SWI/SNF chromatin-remodeling complexes are subdivided into BAF and
PBAF complexes
BAF complexes are defined by either BAF250A or BAF250B as the ARID-containing
subunit (light green ovals), which are mutually exclusive (as denoted by dashed arrow with
dual arrowheads), while PBAF complexes utilize BAF200 (blue oval) as the ARID-
containing subunit. PBAF complexes also incorporate BAF180 (blue oval), which has 6
bromodomains that can bind to acetylated histones. BAF complexes are catalyzed by either
BRG1 or BRM (red ovals), but no single complex contains both as denoted by dashed arrow
with dual arrowheads. In contrast, PBAF is catalyzed exclusively by BRG1 (red oval). A
number of other common subunits (BAFs for BRG1 or BRM associated factors) are also
present (gray ovals from largest to smallest with numbers referring to protein size in KDa),
and some of these subunits are represented by multiple isoforms (as indicated by asterisks)
that are encoded by separate genes although only 1 isoform is present in a single complex
similar to BAF250A-BAF250B and BRG1-BRM.
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Figure 2. Functional compensation of BRG1 and BRM in adult vascular endothelial cells of the
heart
Transmission electron micrographs reveal 2 ultrastructural defects of cardiac endothelial
cells in many of the capillary vessel walls 25 days after temporal induction of the Brg1
mutation. A and B, Dying endothelial cells are present in the capillaries of treated BRG1/
BRM double mutant mice (asterisks). Throughout the cardiac capillary bed, gap junctions
between endothelial cells were intact between healthy cells as well as between affected cells.
Note that even between viable and injured cells the gap junctions are intact (double-
daggers). C, Vascular endothelial cells from treated BRG1/BRM double-mutant mice have
swollen mitochondria (white daggers) and rough endoplasmic reticulum (black daggers),
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which are characteristic changes found in cell death. A and C correspond to the epicardium;
B corresponds to the endocardium. Reprinted from: Willis, et al., 2012 [41], with
permission.
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Table 1





Hypoplastic right ventricle, thin myocardium
Shortened outflow tract Lack of septum












Developmental delay of right ventricle
Defective formation of outflow tract
Defective formation of ventricular septum
Hypotrabeculation
Cardiac progenitor cell differentiation in vitro
N.D. N.D. N.D.
BAF180 Hypoplastic ventriclesDefective formation of ventricular septum Coronary vessel defects N.D. N.D.
BAF60C




BAF155 Yolk sac defects N.D. N.D.
N.D. Does not necessarily infer there is no function for that cell type but can instead reflect either a lack of the appropriate conditional tissue-
specific conditional mutation or insufficient phenotypic analysis.
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